NORETHINDRONE AND MESTRANOL Drug Patent Profile
✉ Email this page to a colleague
When do Norethindrone And Mestranol patents expire, and when can generic versions of Norethindrone And Mestranol launch?
Norethindrone And Mestranol is a drug marketed by Watson Labs and is included in two NDAs.
The generic ingredient in NORETHINDRONE AND MESTRANOL is mestranol; norethindrone. There are eleven drug master file entries for this compound. Additional details are available on the mestranol; norethindrone profile page.
US Patents and Regulatory Information for NORETHINDRONE AND MESTRANOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | NORETHINDRONE AND MESTRANOL | mestranol; norethindrone | TABLET;ORAL-21 | 070758-001 | Jul 1, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs | NORETHINDRONE AND MESTRANOL | mestranol; norethindrone | TABLET;ORAL-28 | 070759-001 | Jul 1, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
